Drug intelligence / Profile preview

Adv-Stat3(-)

Development stage: Preclinical
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies

Overview

Adv-Stat3(-) is an E1A mutant conditionally replicative adenovirus designed as a therapeutic agent for tumors. It operates by selectively replicating within tumor cells and expressing high levels of anti-sense Signal transducer and activator of transcription 3 (Stat3) complementary DNA. This mechanism leads to the inhibition of Stat3, a protein crucial for cell growth and apoptosis, and has demonstrated therapeutic efficacy in breast cancer and melanoma cells.

Targets

STAT3 (Signal Transducer and Activator of Transcription 3)

Beyond the preview

Go deeper on Adv-Stat3(-).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Adv-Stat3(-).

Explore the full profile